<DOC>
	<DOCNO>NCT01225237</DOCNO>
	<brief_summary>A study verify superiority ramosetron hydrochloride ( Irribow Tablets ) placebo male patient diarrhea-predominant irritable bowel syndrome ( D-IBS ) evaluate safety .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Ramosetron Diarrhea-predominant Irritable Bowel Syndrome ( IBS ) Male Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Patients meet Rome III Diagnostic Criteria Loose ( mushy ) watery stool within last 3 month Patients history surgical resection stomach , small intestine large intestine Patients history current diagnosis inflammatory bowel disease ( Crohn 's disease colitis ulcerative ) Patients history current diagnosis colitis ischemic Patients current diagnosis enteritis infectious Patients current diagnosis hyperthyroidism hypothyroidism Patients currently participate another clinical trial ( include postmarketing clinical study ) participate another clinical trial ( include postmarketing clinical study ) within 12 week study Patients history current diagnosis malignant tumor Patients history abuse drug alcohol within 1 year currently abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>diarrhea</keyword>
	<keyword>IBS</keyword>
	<keyword>Colonic disease</keyword>
	<keyword>YM060</keyword>
</DOC>